Radical Prostatectomy News and Research

RSS

Radical prostatectomy is surgery to remove all of the prostate gland and some of the tissue around it, to treat prostate cancer.

One single genomic fingerprinting could potentially miss smaller, more aggressive prostate tumors

While the majority of prostate cancers are slow growing and not fatal, some are aggressive and lethal.

22 Sep 2016

Active surveillance improves health related quality of life in low risk prostate cancer patients

Active surveillance (AS) has become an increasingly important alternative to surgery, chemotherapy, or radiation treatment for men diagnosed with low risk prostate cancer.

25 Jul 2016

Changes in benign tissue adjacent to prostate tumors could better predict recurrence

Changes in benign tissues next to prostate tumors may provide an early warning for patients at higher risk for biochemical recurrence after a radical prostatectomy, a study by researchers at Case Western Reserve University and Johns Hopkins Medical Institutions shows.

6 Jul 2016

MRI-guided focal laser ablation could be feasible, safe in prostate cancer patients

Prostate cancer patients may soon have a new option to treat their disease: laser heat. UCLA researchers have found that focal laser ablation - the precise application of heat via laser to a tumor - is both feasible and safe in men with intermediate risk prostate cancer.

10 Jun 2016

Robotic-assisted radical prostatectomy may reduce risk of blood loss, prolonged hospital stays in obese men

In obese prostate cancer patients, robotic-assisted surgery to remove the prostate reduces the risk of blood loss and prolonged hospital stays, a Loyola Medicine study has found.

23 May 2016

Salvage radical prostatectomy can improve outcomes in prostate cancer patients

Approximately 14 percent of men will be diagnosed with prostate cancer at some point in their lifetimes, according to the National Institutes of Health. Radiation therapy traditionally has been a primary treatment for the cancer, but one-fourth of men have a recurrence of prostate cancer within five years after the therapy.

11 Mar 2016

New study finds link between vitamin D deficiency and aggressive prostate cancer

A new study provides a major link between low levels of vitamin D and aggressive prostate cancer. Northwestern Medicine research showed deficient vitamin D blood levels in men can predict aggressive prostate cancer identified at the time of surgery.

2 Mar 2016

Light reflectance spectroscopy may lead to real-time tissue analysis during prostate cancer surgery

Researchers at UT Southwestern Medical Center have determined that light reflectance spectroscopy can differentiate between malignant and benign prostate tissue with 85 percent accuracy, a finding that may lead to real-time tissue analysis during prostate cancer surgery.

27 Feb 2016

Active surveillance recommended for low-risk prostate cancer

For most men with low-risk prostate cancer, the recommended strategy is active surveillance with regular testing to check for cancer growth rather than immediate treatment, according to guidelines from the American Society of Clinical Oncology.

18 Feb 2016

ASTRO's new research journal 'Advances in Radiation Oncology' closes first issue

Advances in Radiation Oncology, ASTRO's new original research journal, has closed its first issue with research including a phase II clinical trial in prostate cancer, a prospective trial in quality of life for breast cancer patients receiving radiotherapy and several clinical and medical physics reports on the use of stereotactic body radiotherapy.

12 Feb 2016

Study looks at post-treatment resources for prostate cancer patients transitioning to survivorship

The System Partner of Rutgers Cancer Institute of New Jersey, Meridian Health is joining forces with Rutgers Cancer Institute in offering access to a research study aimed at prostate cancer patients who are transitioning to survivorship.

11 Feb 2016

New prognostic biomarker may help determine risk of prostate cancer-related death

Researchers at the University of Copenhagen have identified a new prognostic biomarker: the neuropeptide pro-NPY, which may help determine the risk of dying from prostate cancer. This particular type of protein is very specific to prostate cancer cells and could help identify whether newly diagnosed patients require radical prostatectomy surgery or if it is safe to delay surgery.

28 Jan 2016

New imaging test detects prostate cancer much better than any other tests in use today

Researchers at Thomas Jefferson University have found the method they developed to image the prostate appears to be much better at detecting prostate cancer than any other test — radiographical, biopsy or blood — in use today.

20 Jan 2016

African American men with prostate cancer have significantly lower PSA density than Caucasian men

A new study published in The Journal of Urology revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) than Caucasian men. These findings could have important implications when selecting patients for inclusion in active PCa surveillance programs.

5 Jan 2016

Study: Prostate surgery patients have unrealistic expectations regarding postoperative sexual function

Patients who have undergone radical prostatectomy often have largely unrealistic expectations with regard to their postoperative sexual function, new research shows.

4 Jan 2016

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Transition Therapeutics Inc. announced today that Transition Therapeutics Ireland Limited has entered into an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women's Hospital.

30 Oct 2015

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Myriad Genetics, Inc. (NASDAQ: MYGN) has announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality.

7 Oct 2015

International study provides evidence of clear link between smoking and risk of prostate cancer

Smoking is a known risk factor for the development of various forms of cancer. However, when it comes to the link between smoking and prostate cancer, the findings of previous studies have been contradictory. Now, for the first time, an international study led by MedUni Vienna and Basle University Hospital, has provided evidence of a clear link.

22 Jun 2015

Decipher Prostate Cancer Classifier predicts metastasis in patients treated with salvage radiation therapy

GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant predictor of metastasis in patients treated with postoperative salvage radiation therapy.

30 May 2015

Current fee-for-service models in U.S. healthcare may jeopardize prostate surgery patients

A "perverse disincentive" for hospitals that have invested in expensive technology for robotic surgery may be jeopardizing prostate cancer patients who seek out the procedure, concluded a new study led by Henry Ford Hospital researchers.

18 May 2015